Fig. 6: Biomarker verification in an independent cohort.
From: Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD
Serum levels of a IGFBP7, b SSc5D, c SEMA4D in samples from 128 patients with MASLD fibrosis score (F0–F4) in testing cohort (F0/F1, n = 38; F2, n = 38; F3/F4, n = 52). Values from biological replicates are shown in box and whisker plots, data are median (horizontal line), interquartile range (boxes) and 10–90% percentile (error bars). A two-sided Student’s t-test was used to test the statistical significance. *p < 0.05, vs. F0/F1 samples. d AUROC curve to show the predictive value of this set of biomarkers to distinguish the individual MASLD fibrosis F-scores (F0–F1 versus F2 versus F3–F4); e Confusion matrix of the hold-out set (n = 8 F0/F1; n = 8 F2; n = 22 F3/F4) of predicted and true classes; f Sensitivity and specificity as calculated from the LGBM classifier Confusion Matrix.
